1. Home
  2. PKG vs GMAB Comparison

PKG vs GMAB Comparison

Compare PKG & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Packaging Corporation of America

PKG

Packaging Corporation of America

N/A

Current Price

$211.86

Market Cap

17.4B

ML Signal

N/A

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

N/A

Current Price

$25.83

Market Cap

19.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PKG
GMAB
Founded
1867
1999
Country
United States
Denmark
Employees
13600
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.4B
19.1B
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
PKG
GMAB
Price
$211.86
$25.83
Analyst Decision
Buy
Strong Buy
Analyst Count
7
8
Target Price
$238.00
$39.81
AVG Volume (30 Days)
853.1K
1.6M
Earning Date
04-22-2026
05-07-2026
Dividend Yield
2.36%
N/A
EPS Growth
N/A
N/A
EPS
8.58
N/A
Revenue
$8,989,300,000.00
N/A
Revenue This Year
$14.39
$17.80
Revenue Next Year
$4.34
$14.86
P/E Ratio
$24.74
$1.90
Revenue Growth
7.23
N/A
52 Week Low
$172.72
$17.24
52 Week High
$249.51
$35.43

Technical Indicators

Market Signals
Indicator
PKG
GMAB
Relative Strength Index (RSI) 40.90 39.54
Support Level $209.93 $24.95
Resistance Level $216.77 $33.75
Average True Range (ATR) 5.04 0.54
MACD 0.08 0.14
Stochastic Oscillator 47.65 45.86

Price Performance

Historical Comparison
PKG
GMAB

About PKG Packaging Corporation of America

Packaging Corp. of America is the third-largest containerboard and corrugated packaging manufacturer in the United States. It produces over 5 million tons of containerboard annually. The company's share of the domestic containerboard market is roughly 10%. PCA differentiates itself from larger competitors by focusing on smaller customers and operating with a high degree of flexibility.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: